Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX4 | Q96LA9 | 7/20 | 0.56 |
| ▸ | UNG | P13051 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 2/20 | 0.47 |
| ▸ | PKM | P14618 | 2/20 | 0.47 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.47 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.47 |
| ▸ | RELA | Q04206 | 2/20 | 0.47 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.47 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.45 |
| ▸ | MMP13 | P45452 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21221823 | 0.83 | P2RX3 (0.52) | UNG | |
| SCHEMBL21221828 | 0.82 | UNG (0.56) | UNG | |
| SCHEMBL21221785 | 0.82 | UNG (0.60) | UNG | |
| SCHEMBL15251878 | 0.81 | MAPT (0.62) | RAB9ANPC1TP53 | |
| SCHEMBL21578904 | 0.77 | MRGPRX4 (0.76) | MRGPRX4SMN1; SMN2RAB9AKDM4ENPC1 | |
| SCHEMBL21221726 | 0.76 | UNG (0.59) | UNGTP53 | |
| SCHEMBL12885852 | 0.76 | MRGPRX4 (0.74) | MRGPRX4SMN1; SMN2RAB9AKDM4ENPC1 | |
| SCHEMBL21221786 | 0.75 | UNG (0.58) | UNG | |
| SCHEMBL21221698 | 0.75 | MRGPRX4 (0.72) | MRGPRX4SMN1; SMN2RAB9AKDM4ENPC1 | |
| SCHEMBL6960292 | 0.75 | MRGPRX4 (0.72) | MRGPRX4SMN1; SMN2RAB9AKDM4ENPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10617706-B2 | Compounds for cancer chemotherapeutic sensitization | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2020-04-14 | — | — | US | disclosed |
| US-20190240244-A1 | COMPOUNDS FOR CANCER CHEMOTHERAPEUTIC SENSITIZATION | REGENTS OF THE UNIVERSITY OF MINNESOTA | 2019-08-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10617706-B2 | Compounds for cancer chemotherapeutic sensitization | ABCC1, MCL1, ABCC3 | MRGPRX4 636/4885UNG 4250/4885SMN1; SMN2 3011/4885 |
| US-20190240244-A1 | COMPOUNDS FOR CANCER CHEMOTHERAPEUTIC SENSITIZATION | ABCC1, MCL1, ABCC3 | MRGPRX4 636/4885UNG 4250/4885SMN1; SMN2 3011/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.